Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24
Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which ha...
Saved in:
Published in | Acta pharmacologica Sinica Vol. 30; no. 4; pp. 467 - 477 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.04.2009
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.
Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.
Conclusions: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. |
---|---|
AbstractList | The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin.
ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.
The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.
This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin.AIMThe aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin.ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.METHODSZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis.The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.RESULTSThe combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells.This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.CONCLUSIONThis study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplatin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. Conclusion: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by the combined use of ZD55-IL-24 and cisplafin. Methods: ZD55-IL-24 is an oncolytic adenovirus that harbors interleukin 24 (IL-24), which has a strong antitumor effect and was identified and evaluated by PCR, RT-PCR, and Western blot analysis. Enhancement of cancer cell death using a combination of ZD55-IL-24 and cisplatin was assessed in several cancer cell lines by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and cytopathic effect (CPE) assay. Apoptosis induction by treatment with ZD55-IL-24 and/or cisplatin was detected in BEL7404 and SMMC7721 by morphological evaluation, apoptotic cell staining, and flow cytometry analysis. In addition, negative effects on normal cells were evaluated in the L-02 cell line using the MTT assay, the CPE assay, morphological evaluation, apoptotic cell staining, and flow cytometry analysis. Results: The combination of ZD55-IL-24 and cisplatin, which is superior to ZD55-IL-24, cisplatin, and ZD55-EGFP, as well as ZD55-EGFP plus cisplatin, resulted in a significantly increased effect. Most importantly, conjugation of ZD55-IL-24 with cisplatin had toxic effects equal to that of cisplatin and did not have overlapping toxicities in normal cells. Conclusions: This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose. |
Author | Yu-mei WU Kang-jian ZHANG Xue-tian YUE Yi-qiang WANG Yi YANG Gong-chu LI Na LI Yi-gang WANG |
AuthorAffiliation | Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, China Department of Surgery, Duchang People's Hospital, Jiujiang 332600, China |
Author_xml | – sequence: 1 givenname: Yu-mei surname: Wu fullname: Wu, Yu-mei organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 2 givenname: Kang-jian surname: Zhang fullname: Zhang, Kang-jian organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 3 givenname: Xue-tian surname: Yue fullname: Yue, Xue-tian organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 4 givenname: Yi-qiang surname: Wang fullname: Wang, Yi-qiang organization: Department of Surgery, Duchang People's Hospital – sequence: 5 givenname: Yi surname: Yang fullname: Yang, Yi organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 6 givenname: Gong-chu surname: Li fullname: Li, Gong-chu organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 7 givenname: Na surname: Li fullname: Li, Na organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University – sequence: 8 givenname: Yi-gang surname: Wang fullname: Wang, Yi-gang email: wangyigang43@163.com organization: Xinyuan Institute of Medicine and Biotechnology, College of Life Science, Zhejiang Sci-Tech University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19270721$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kktv1DAUhS1URB-wYo8sFmwgU78SJ5tKVSlQaRAbWFv2jTNxSeypnRTNv8fRDBQqWNmSv3t0zj0-RUc-eIvQS0pWlPD6XG_TihHSrGj1BJ1QKcpCslIc5XslaSFIzY_RaUq3hHDGafMMHdOGSSIZPUH9te-1BztaP-HQ4WkeQ8RghwG3Vk89NjsMYTTOO7_B4NJ20JPz-IfLb9rj4CEMu8kB1q314d7FOWHQMe4W_vP7y0Ke36wLJp6jp50ekn1xOM_Qtw_XX68-FesvH2-uLtcFCEmmou1MxxqhGZjWAK8oKWVrS81Lki23ANQQzgm0pRFdaWTZQk2s6aw1VdNqxs_QxV53O5vRtpBzRT2obXSjjjsVtFN_v3jXq024V4IQxqomC7w5CMRwN9s0qdGlZSHa2zAnlXdKmKA8g68fgbdhjj6HU4xykrVqkaFXf9r57eNXAxl4uwcghpSi7R4QopZ-Ve5XLf0qWmWaPqLBTbmQsGRxw39m3u1nUlb2GxsffP4bP8SCPvjNXZ5QRsP3zg1WsaaWss6_6CevWcRU |
CitedBy_id | crossref_primary_10_1007_s00432_014_1835_8 crossref_primary_10_18632_oncotarget_24539 crossref_primary_10_1007_s13277_014_2353_7 crossref_primary_10_4251_wjgo_v16_i7_2867 crossref_primary_10_1007_s13277_015_3098_7 crossref_primary_10_1124_mol_109_061820 crossref_primary_10_3390_ijms23010072 crossref_primary_10_1007_s11010_010_0397_6 crossref_primary_10_1038_cgt_2012_40 crossref_primary_10_1517_14712598_2010_481668 crossref_primary_10_3748_wjg_v22_i1_326 crossref_primary_10_1002_ijc_25948 crossref_primary_10_1089_ars_2017_7058 crossref_primary_10_1089_ars_2017_7157 crossref_primary_10_3109_0284186X_2011_621447 crossref_primary_10_3389_fonc_2023_1172292 crossref_primary_10_1186_s12985_017_0818_1 crossref_primary_10_1016_j_cytogfr_2012_08_004 crossref_primary_10_1016_j_etap_2013_08_004 crossref_primary_10_1016_j_dit_2013_09_001 crossref_primary_10_1007_s10495_016_1276_8 crossref_primary_10_1186_1756_9966_28_81 crossref_primary_10_1186_1750_2187_8_15 crossref_primary_10_3390_inorganics12070177 crossref_primary_10_18632_oncotarget_3769 crossref_primary_10_1007_s13277_013_1149_5 crossref_primary_10_1089_cbr_2014_1642 crossref_primary_10_1021_acs_chemrestox_9b00097 crossref_primary_10_3892_or_2012_1636 crossref_primary_10_3390_cancers12040809 |
Cites_doi | 10.1089/hum.2005.16.845 10.1056/NEJM198706043162302 10.1073/pnas.171315198 10.1038/nrc2167 10.1111/j.1745-7254.2007.00672.x 10.4161/cbt.458 10.1038/sj.cgt.7700954 10.1007/BF00263902 10.1038/sj.gt.3301377 10.1016/0378-4274(89)90125-2 10.1517/14712598.1.3.525 10.1038/sj.cgt.7700915 10.1007/s11010-007-9514-6 10.1007/978-0-387-68969-2_16 10.1016/j.ymthe.2004.03.014 10.1038/sj.cr.7290191 10.1016/S0270-9295(03)00089-5 10.1016/j.ymthe.2004.12.003 10.1038/sj.onc.1204897 10.1038/sj.cr.7310005 10.1038/sj.onc.1205116 10.1038/78638 10.1038/205698a0 |
ContentType | Journal Article |
Copyright | CPS and SIMM 2009 Copyright Nature Publishing Group Apr 2009 Copyright © 2009 CPS and SIMM 2009 CPS and SIMM |
Copyright_xml | – notice: CPS and SIMM 2009 – notice: Copyright Nature Publishing Group Apr 2009 – notice: Copyright © 2009 CPS and SIMM 2009 CPS and SIMM |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7TK 7TO 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1038/aps.2009.16 |
DatabaseName | 中文科技期刊数据库 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24 |
EISSN | 1745-7254 |
EndPage | 477 |
ExternalDocumentID | PMC4002269 1730258301 19270721 10_1038_aps_2009_16 29877832 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -05 -0E -Q- -SE -S~ .3N 0R~ 188 1OC 23M 2RA 2WC 31~ 36B 3V. 4.4 53G 5GY 5VR 5VS 6J9 70F 7X7 8-1 88E 8FI 8FJ 8R4 8R5 8RM 92L 92M 9D9 9DE A8Z AADWK AANZL AAPBV AAWBL AAYJO AAZLF ABAWZ ABDEU ABKZE ABUWG ACBMV ACBRV ACBYP ACGFO ACGFS ACIGE ACIWK ACKTT ACPRK ACRQY ACTTH ACVWB ACXQS ADBBV ADFRT ADHDB ADMDM ADQMX ADRAZ ADYYL AEDAW AEFTE AEJRE AENEX AEXYK AFBPY AFKRA AFRAH AFSHS AFUIB AFZJQ AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AINHJ AJDOV AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AOIJS AXYYD BAWUL BBAFP BBNVY BENPR BFHJK BHPHI BKKNO BPHCQ BVXVI C1A CAG CAJEE CAJUS CCEZO CDYEO CHBEP CIEJG CO8 COF CQIGP CS3 CW9 CXBCV DIK DNIVK E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FA0 FDQFY FERAY FIZPM FSGXE FYUFA GX1 HCIFZ HH5 HYE HZI HZ~ JSO JUIAU JZLTJ K97 KQ8 LH4 LW6 M1P M48 M7P MK0 NQJWS NYICJ O9- OK1 OVD P2P P6G PQEST PQQKQ PQUKI PROAC PSQYO Q-- Q-4 Q2X R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SRMVM SV3 SWTZT T8U TAOOD TBHMF TDRGL TEORI TR2 TSG U1F U1G U5E U5O UKHRP UMP UZ5 W91 ~88 ~NG ~WA 406 AACDK AASML AATNV AAXDM ABAKF ABZZP ACAOD ACMJI ACZOJ AEFQL AEMSY AESKC AEVLU AFBBN AGQEE AIGIU AJAOE ALIPV CCPQU DPUIP FIGPU HMCUK IWAJR LGEZI LOTEE NADUK NXXTH ROL SOHCF AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT SOJ CGR CUY CVF ECM EIF NPM 7QP 7QR 7T5 7TK 7TO 7U9 7XB 8FD 8FE 8FH 8FK ABRTQ AZQEC DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PJZUB PKEHL PPXIY PQGLB PRINS PUEGO 7X8 5PM |
ID | FETCH-LOGICAL-c470t-dfbf294a2cbdbc361057de5a350270dcc1b0330cd5b4f5b75dc80ebfeeb69da23 |
IEDL.DBID | M48 |
ISSN | 1671-4083 1745-7254 |
IngestDate | Thu Aug 21 18:20:22 EDT 2025 Thu Jul 10 18:19:54 EDT 2025 Sat Aug 23 13:25:05 EDT 2025 Thu Apr 03 07:01:37 EDT 2025 Thu Apr 24 22:51:00 EDT 2025 Tue Jul 01 02:04:08 EDT 2025 Fri Feb 21 02:38:44 EST 2025 Thu Nov 24 20:33:35 EST 2022 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | apoptosis MDA-7/IL-24 oncolytic adenovirus cisplatin |
Language | English |
License | http://www.springer.com/tdm |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-dfbf294a2cbdbc361057de5a350270dcc1b0330cd5b4f5b75dc80ebfeeb69da23 |
Notes | cisplatin; MDA-7/IL-24; oncolytic adenovirus; apoptosis MDA-7/IL-24 oncolytic adenovirus R730.53 R735.2 apoptosis cisplatin 31-1347/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.nature.com/articles/aps200916.pdf |
PMID | 19270721 |
PQID | 213026984 |
PQPubID | 28815 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4002269 proquest_miscellaneous_67102413 proquest_journals_213026984 pubmed_primary_19270721 crossref_primary_10_1038_aps_2009_16 crossref_citationtrail_10_1038_aps_2009_16 springer_journals_10_1038_aps_2009_16 chongqing_backfile_29877832 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-04-01 |
PublicationDateYYYYMMDD | 2009-04-01 |
PublicationDate_xml | – month: 04 year: 2009 text: 2009-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: United States – name: Shanghai |
PublicationTitle | Acta pharmacologica Sinica |
PublicationTitleAbbrev | Acta Pharmacol Sin |
PublicationTitleAlternate | Acta Pharmacologica Sinica |
PublicationYear | 2009 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Fisher, Gopalkrishnan, Chada, Ramesh, Grimm, Rosenfeld (CR4) 2003; 2 Hajra, Tan, Liu (CR23) 2008; 622 Zhao, Gu, Dong, Zhang, Zhong, He (CR12) 2005; 16 Khuri, Nemunaitis, Ganly, Arseneau, Tannock, Romel (CR20) 2000; 6 Jiang, Lin, Su, Goldstein, Fisher (CR1) 1995; 11 Fillastre, Raguenez-Viotte (CR27) 1989; 46 Kelland (CR13) 2007; 7 Kirn (CR26) 2001; 1 Morton, Rugman, Dorman, Stoney, Wilson, McCormick (CR15) 1985; 15 Miyahara, Banerjee, Kawano, Efferson, Tsuda, Miyahara (CR6) 2006; 13 Zhang, Zou, Luo, Li, Wang, Sun (CR10) 2003; 13 Williams, Birch, Einhorn, Irwin, Greco, Loehrer (CR16) 1987; 316 Nishikawa, Ramesh, Munshi, Chada, Meyn (CR7) 2004; 9 Chada, Cunningham, Zhang, Su, Mhashilkar, Ekmekcioglu (CR9) 2003; 7 Liu, Qiu, Zou, Pei, Gu, Luo (CR11) 2005; 11 Huang, Madireddi, Gopalkrishnan, Leszczyniecka, Su, Lebedeva (CR21) 2001; 20 Chada, Nemunaitis, Tong, Zhang, Su, Mhashilkar (CR8) 2001; 8 Kirn (CR25) 2001; 8 Chada, Mhashilkar, Liu, Nishikawa, Bocangel, Zheng (CR5) 2006; 13 Uyama, Hatano, Maetani, Isoda, Shibata, Taura (CR24) 2008; 35 Pan, Liu, Liu, Cai, Wang, Qian (CR17) 2007; 304 Xiong, Peng, Tan (CR19) 2007; 38 Pan, Zhong, Liu, Liu, Cai, Wang (CR18) 2007; 28 Rosenberg, Vancamp, Krigas (CR14) 1965; 205 Lebedeva, Su, Chang, Kitada, Reed, Fisher (CR2) 2002; 21 Arany, Safirstein (CR28) 2003; 23 Su, Lebedeva, Gopalkrishnan, Goldstein, Stein, Reed (CR3) 2001; 98 Liu, Gu (CR22) 2006; 16 S Chada (BFaps200916_CR9) 2003; 7 PB Fisher (BFaps200916_CR4) 2003; 2 S Chada (BFaps200916_CR5) 2006; 13 N Uyama (BFaps200916_CR24) 2008; 35 D Kirn (BFaps200916_CR25) 2001; 8 EY Huang (BFaps200916_CR21) 2001; 20 QW Pan (BFaps200916_CR17) 2007; 304 XY Liu (BFaps200916_CR22) 2006; 16 H Jiang (BFaps200916_CR1) 1995; 11 J Xiong (BFaps200916_CR19) 2007; 38 XY Liu (BFaps200916_CR11) 2005; 11 Z Su (BFaps200916_CR3) 2001; 98 D Kirn (BFaps200916_CR26) 2001; 1 FR Khuri (BFaps200916_CR20) 2000; 6 KM Hajra (BFaps200916_CR23) 2008; 622 RP Morton (BFaps200916_CR15) 1985; 15 QW Pan (BFaps200916_CR18) 2007; 28 L Kelland (BFaps200916_CR13) 2007; 7 I Arany (BFaps200916_CR28) 2003; 23 L Zhao (BFaps200916_CR12) 2005; 16 S Chada (BFaps200916_CR8) 2001; 8 ZL Zhang (BFaps200916_CR10) 2003; 13 IV Lebedeva (BFaps200916_CR2) 2002; 21 SD Williams (BFaps200916_CR16) 1987; 316 T Nishikawa (BFaps200916_CR7) 2004; 9 R Miyahara (BFaps200916_CR6) 2006; 13 JP Fillastre (BFaps200916_CR27) 1989; 46 B Rosenberg (BFaps200916_CR14) 1965; 205 11313778 - Gene Ther. 2001 Jan;8(2):89-98 17625587 - Nat Rev Cancer. 2007 Aug;7(8):573-84 18031615 - Acta Pharmacol Sin. 2007 Dec;28(12):1996-2004 13680535 - Semin Nephrol. 2003 Sep;23(5):460-4 17593824 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):433-6 11526239 - Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7 15194048 - Mol Ther. 2004 Jun;9(6):818-28 2414023 - Cancer Chemother Pharmacol. 1985;15(3):283-9 11850799 - Oncogene. 2002 Jan 24;21(5):708-18 14728805 - Cell Res. 2003 Dec;13(6):481-9 17577631 - Mol Cell Biochem. 2007 Oct;304(1-2):315-23 8545104 - Oncogene. 1995 Dec 21;11(12):2477-86 18546629 - Adv Exp Med Biol. 2008;622:197-208 2437455 - N Engl J Med. 1987 Jun 4;316(23):1435-40 16543916 - Cancer Gene Ther. 2006 Aug;13(8):753-61 16467873 - Cell Res. 2006 Jan;16(1):25-30 10932224 - Nat Med. 2000 Aug;6(8):879-85 16000066 - Hum Gene Ther. 2005 Jul;16(7):845-58 14508078 - Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37 14287410 - Nature. 1965 Feb 13;205:698-9 2650023 - Toxicol Lett. 1989 Mar;46(1-3):163-75 16282987 - Cancer Gene Ther. 2006 May;13(5):490-502 15771956 - Mol Ther. 2005 Apr;11(4):531-41 18487912 - Gan To Kagaku Ryoho. 2008 May;35(5):775-80 11704829 - Oncogene. 2001 Oct 25;20(48):7051-63 11727523 - Expert Opin Biol Ther. 2001 May;1(3):525-38 |
References_xml | – volume: 16 start-page: 845 year: 2005 end-page: 58 ident: CR12 article-title: Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer publication-title: Hum Gene Ther doi: 10.1089/hum.2005.16.845 – volume: 316 start-page: 1435 year: 1987 end-page: 40 ident: CR16 article-title: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide publication-title: N Engl J Med doi: 10.1056/NEJM198706043162302 – volume: 98 start-page: 10332 year: 2001 end-page: 7 ident: CR3 article-title: A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.171315198 – volume: 7 start-page: 573 year: 2007 end-page: 84 ident: CR13 article-title: The resurgence of platinum-based cancer chemotherapy publication-title: Nat Rev Cancer doi: 10.1038/nrc2167 – volume: 28 start-page: 1996 year: 2007 end-page: 2004 ident: CR18 article-title: Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus publication-title: Acta Pharmacol Sin doi: 10.1111/j.1745-7254.2007.00672.x – volume: 2 start-page: S23 year: 2003 end-page: S37 ident: CR4 article-title: mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic publication-title: Cancer Biol Ther doi: 10.4161/cbt.458 – volume: 13 start-page: 753 year: 2006 end-page: 61 ident: CR6 article-title: Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700954 – volume: 7 start-page: S446 year: 2003 ident: CR9 article-title: INGN 241 (Ad-mda-7) induces widespread apoptosis and activates the immune system in patients with advanced cancer publication-title: Mol Ther – volume: 15 start-page: 283 year: 1985 end-page: 9 ident: CR15 article-title: Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial publication-title: Cancer Chemother Pharmacol doi: 10.1007/BF00263902 – volume: 8 start-page: 89 year: 2001 end-page: 98 ident: CR25 article-title: Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? publication-title: Gene Ther doi: 10.1038/sj.gt.3301377 – volume: 11 start-page: 2477 year: 1995 end-page: 86 ident: CR1 article-title: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression publication-title: Oncogene – volume: 46 start-page: 163 year: 1989 end-page: 75 ident: CR27 article-title: Cisplatin nephrotoxicity publication-title: Toxicol Lett doi: 10.1016/0378-4274(89)90125-2 – volume: 1 start-page: 525 year: 2001 end-page: 38 ident: CR26 article-title: Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.1.3.525 – volume: 13 start-page: 490 year: 2006 end-page: 502 ident: CR5 article-title: mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700915 – volume: 35 start-page: 775 year: 2008 end-page: 80 ident: CR24 article-title: Efficacy and toxicity of transcatheter arterial chemoembolization with cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma publication-title: Gan To Kagaku Ryoho – volume: 304 start-page: 315 year: 2007 end-page: 23 ident: CR17 article-title: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL publication-title: Mol Cell Biochem doi: 10.1007/s11010-007-9514-6 – volume: 622 start-page: 197 year: 2008 end-page: 208 ident: CR23 article-title: Defective apoptosis underlies chemoresistance in ovarian cancer publication-title: Adv Exp Med Biol doi: 10.1007/978-0-387-68969-2_16 – volume: 9 start-page: 818 year: 2004 end-page: 28 ident: CR7 article-title: Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation publication-title: Mol Ther doi: 10.1016/j.ymthe.2004.03.014 – volume: 13 start-page: 481 year: 2003 end-page: 99 ident: CR10 article-title: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy publication-title: Cell Res doi: 10.1038/sj.cr.7290191 – volume: 23 start-page: 460 year: 2003 end-page: 4 ident: CR28 article-title: Cisplatin nephrotoxicity publication-title: Semin Nephrol doi: 10.1016/S0270-9295(03)00089-5 – volume: 11 start-page: 531 year: 2005 end-page: 41 ident: CR11 article-title: Effective gene-virotherapy for complete eradication of tumor mediated by the combination of htrail (tnfsf10) and plasminogen k5 publication-title: Mol Therapy doi: 10.1016/j.ymthe.2004.12.003 – volume: 20 start-page: 7051 year: 2001 end-page: 63 ident: CR21 article-title: Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties publication-title: Oncogene doi: 10.1038/sj.onc.1204897 – volume: 16 start-page: 25 year: 2006 end-page: 30 ident: CR22 article-title: Targeting gene-virotherapy of cancer publication-title: Cell Res doi: 10.1038/sj.cr.7310005 – volume: 21 start-page: 708 year: 2002 end-page: 18 ident: CR2 article-title: The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells publication-title: Oncogene doi: 10.1038/sj.onc.1205116 – volume: 8 start-page: S3 issue: Suppl 2 year: 2001 ident: CR8 article-title: A Phase I dose-escalation study of Ad-mda7 (INGN 241) in patients with advanced carcinoma publication-title: Cancer Gene Ther – volume: 6 start-page: 879 year: 2000 end-page: 85 ident: CR20 article-title: A controlled trial of ONYX-015, a replication-selective adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer publication-title: Nat Med doi: 10.1038/78638 – volume: 38 start-page: 433 year: 2007 end-page: 6 ident: CR19 article-title: Effects of adenoviral-mediated mda-7/IL-24 gene infection on the growth and drug-resistance of drug-resistant ovarian cancer cell lines publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban – volume: 205 start-page: 698 year: 1965 end-page: 9 ident: CR14 article-title: Inhibition of cell division in by electrolysis products from a platinum electrode publication-title: Nature doi: 10.1038/205698a0 – volume: 8 start-page: 89 year: 2001 ident: BFaps200916_CR25 publication-title: Gene Ther doi: 10.1038/sj.gt.3301377 – volume: 8 start-page: S3 issue: Suppl 2 year: 2001 ident: BFaps200916_CR8 publication-title: Cancer Gene Ther – volume: 16 start-page: 845 year: 2005 ident: BFaps200916_CR12 publication-title: Hum Gene Ther doi: 10.1089/hum.2005.16.845 – volume: 1 start-page: 525 year: 2001 ident: BFaps200916_CR26 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.1.3.525 – volume: 20 start-page: 7051 year: 2001 ident: BFaps200916_CR21 publication-title: Oncogene doi: 10.1038/sj.onc.1204897 – volume: 16 start-page: 25 year: 2006 ident: BFaps200916_CR22 publication-title: Cell Res doi: 10.1038/sj.cr.7310005 – volume: 15 start-page: 283 year: 1985 ident: BFaps200916_CR15 publication-title: Cancer Chemother Pharmacol doi: 10.1007/BF00263902 – volume: 7 start-page: S446 year: 2003 ident: BFaps200916_CR9 publication-title: Mol Ther – volume: 13 start-page: 481 year: 2003 ident: BFaps200916_CR10 publication-title: Cell Res doi: 10.1038/sj.cr.7290191 – volume: 304 start-page: 315 year: 2007 ident: BFaps200916_CR17 publication-title: Mol Cell Biochem doi: 10.1007/s11010-007-9514-6 – volume: 7 start-page: 573 year: 2007 ident: BFaps200916_CR13 publication-title: Nat Rev Cancer doi: 10.1038/nrc2167 – volume: 622 start-page: 197 year: 2008 ident: BFaps200916_CR23 publication-title: Adv Exp Med Biol doi: 10.1007/978-0-387-68969-2_16 – volume: 21 start-page: 708 year: 2002 ident: BFaps200916_CR2 publication-title: Oncogene doi: 10.1038/sj.onc.1205116 – volume: 35 start-page: 775 year: 2008 ident: BFaps200916_CR24 publication-title: Gan To Kagaku Ryoho – volume: 316 start-page: 1435 year: 1987 ident: BFaps200916_CR16 publication-title: N Engl J Med doi: 10.1056/NEJM198706043162302 – volume: 11 start-page: 531 year: 2005 ident: BFaps200916_CR11 publication-title: Mol Therapy doi: 10.1016/j.ymthe.2004.12.003 – volume: 11 start-page: 2477 year: 1995 ident: BFaps200916_CR1 publication-title: Oncogene – volume: 9 start-page: 818 year: 2004 ident: BFaps200916_CR7 publication-title: Mol Ther doi: 10.1016/j.ymthe.2004.03.014 – volume: 205 start-page: 698 year: 1965 ident: BFaps200916_CR14 publication-title: Nature doi: 10.1038/205698a0 – volume: 38 start-page: 433 year: 2007 ident: BFaps200916_CR19 publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban – volume: 46 start-page: 163 year: 1989 ident: BFaps200916_CR27 publication-title: Toxicol Lett doi: 10.1016/0378-4274(89)90125-2 – volume: 13 start-page: 753 year: 2006 ident: BFaps200916_CR6 publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700954 – volume: 2 start-page: S23 year: 2003 ident: BFaps200916_CR4 publication-title: Cancer Biol Ther doi: 10.4161/cbt.458 – volume: 13 start-page: 490 year: 2006 ident: BFaps200916_CR5 publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700915 – volume: 28 start-page: 1996 year: 2007 ident: BFaps200916_CR18 publication-title: Acta Pharmacol Sin doi: 10.1111/j.1745-7254.2007.00672.x – volume: 23 start-page: 460 year: 2003 ident: BFaps200916_CR28 publication-title: Semin Nephrol doi: 10.1016/S0270-9295(03)00089-5 – volume: 98 start-page: 10332 year: 2001 ident: BFaps200916_CR3 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.171315198 – volume: 6 start-page: 879 year: 2000 ident: BFaps200916_CR20 publication-title: Nat Med doi: 10.1038/78638 – reference: 16467873 - Cell Res. 2006 Jan;16(1):25-30 – reference: 17625587 - Nat Rev Cancer. 2007 Aug;7(8):573-84 – reference: 11313778 - Gene Ther. 2001 Jan;8(2):89-98 – reference: 8545104 - Oncogene. 1995 Dec 21;11(12):2477-86 – reference: 16000066 - Hum Gene Ther. 2005 Jul;16(7):845-58 – reference: 16543916 - Cancer Gene Ther. 2006 Aug;13(8):753-61 – reference: 13680535 - Semin Nephrol. 2003 Sep;23(5):460-4 – reference: 11850799 - Oncogene. 2002 Jan 24;21(5):708-18 – reference: 18031615 - Acta Pharmacol Sin. 2007 Dec;28(12):1996-2004 – reference: 18487912 - Gan To Kagaku Ryoho. 2008 May;35(5):775-80 – reference: 11704829 - Oncogene. 2001 Oct 25;20(48):7051-63 – reference: 16282987 - Cancer Gene Ther. 2006 May;13(5):490-502 – reference: 14508078 - Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S23-37 – reference: 15771956 - Mol Ther. 2005 Apr;11(4):531-41 – reference: 17577631 - Mol Cell Biochem. 2007 Oct;304(1-2):315-23 – reference: 2437455 - N Engl J Med. 1987 Jun 4;316(23):1435-40 – reference: 14287410 - Nature. 1965 Feb 13;205:698-9 – reference: 15194048 - Mol Ther. 2004 Jun;9(6):818-28 – reference: 2414023 - Cancer Chemother Pharmacol. 1985;15(3):283-9 – reference: 17593824 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):433-6 – reference: 14728805 - Cell Res. 2003 Dec;13(6):481-9 – reference: 11526239 - Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7 – reference: 2650023 - Toxicol Lett. 1989 Mar;46(1-3):163-75 – reference: 18546629 - Adv Exp Med Biol. 2008;622:197-208 – reference: 11727523 - Expert Opin Biol Ther. 2001 May;1(3):525-38 – reference: 10932224 - Nat Med. 2000 Aug;6(8):879-85 |
SSID | ssj0032319 |
Score | 2.0301719 |
Snippet | Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells... Aim: The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells... The aim of this study was to creatively implement a novel chemo-gene-virotherapeutic strategy and further strengthen the antitumor effect in cancer cells by... |
SourceID | pubmedcentral proquest pubmed crossref springer chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 467 |
SubjectTerms | Adenoviridae - genetics Antineoplastic Agents - pharmacology Apoptosis Biomedical and Life Sciences Biomedicine Cell death Cell Line Cisplatin - pharmacology Combined Modality Therapy Dose-Response Relationship, Drug Genetic Therapy Humans Immunology Interleukins - genetics Internal Medicine MDA-7/IL-24 Medical Microbiology Neoplasms - pathology Neoplasms - therapy Oncolytic Virotherapy Original original-article Pharmacology/Toxicology Vaccine 流式细胞仪分析 溶瘤腺病毒 白细胞介素24 肿瘤细胞死亡 腺病毒携带 诱导凋亡作用 |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLig8g7Lw4fSA2q0Sewk9glV0Koginpopb1FfqW7Apxtsltp_z0zea2WVhwjW47lGXu-mbG_IeRAJdrluUhDZxMbgr_BQykMfvISvIfUxRrjkOc_s7Mr_n2Wzvq7OU1_rXI4E9uD2lYGY-TTBDNsmRT88_ImxKJRmFztK2g8JI-QuQyVOp-N_hYD6ILoN85ydJME65_nRUxM1bLpuCrjllRhXvnrGzAVu8bpDuK8e3Hyn-xpa5RO98mTHk3S4078T8kD55-Rw4uOjnpzRC-3r6uaI3pIL7ZE1ZvnZH7i5yh0DBDSqqSr9Z-qphjKpxaRIdUbCouj2xoS1CyaJV6c8xRjt1R5WnkYaQNjUwWnV3W7qNcNNaqu8ekUPf96HObTbz_ChL8gV6cnl1_Owr7yQmh4Hq1CW-oykVwlRlttWIbFgK1LFUvBi42sMbGOGIuMTTUvU52n1ojI6dI5nUmrEvaS7PnKu9eEQgfJ0lJqBeCHl0oBxMlM7ISRQpW5C8hkXH6w3OYX8lEViRSgQSwJyKdBIIXpScuxdsbvok2eM1GAJLGUpiziLCAHY-dlx9Vxf7fJINmi37DQNqhXQD6MrbDTcM2Vd9W6KTIEY2DzA_Kq04LtTySsCrjSAcl39GPsgBzeuy1-MW-5vDmCqEwG5OOgSds53TP3N_-d-4Q8HpJdUfyW7K3qtXsHmGml37c74y_0rhje priority: 102 providerName: ProQuest |
Title | Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24 |
URI | http://lib.cqvip.com/qk/95561A/20094/29877832.html https://link.springer.com/article/10.1038/aps.2009.16 https://www.ncbi.nlm.nih.gov/pubmed/19270721 https://www.proquest.com/docview/213026984 https://www.proquest.com/docview/67102413 https://pubmed.ncbi.nlm.nih.gov/PMC4002269 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwEB7t48IF8SYUig_LHtCGzcN5-IBQC60WRKsKbaXeIttxaMWSdJMW0X_PTNO06m4PnKIoE8eyx5lvZuxvAM6kp0wUxYFtUi-10d_gtog13fIMvYfAuIrikINheDXm3ybB5AiaYpybAawOunZUT2pc3nz4e7v6hAv-Y31kPL6U86omnnTDYzhFkxRRKYMB36YTfAQxhIPdMCKHKfY3B_XuvEz0CtMi_3mLRmPfTN3Dnve3UN7Jo67NU_8RPNzgStapFeExHJn8CZyPamLq1QW73p2zqi7YORvtKKtXT2Hay6c0_RQqZEXGFsvfRckoqM9SwohMrRiqplpXk2B6Vs1pC13OKIrLZM6KHFtaYdtM4n-s-DMrlxXTsizpEBUbfOnY0eXX77bHn8G437v-fGVvajDYmkfOwk4zlXmCS0-rVGk_pLLAqQmkH6A_66Rau8rxfUengeJZoKIg1bFjVGaMCkUqPf85nORFbl4CQwHhB5lQEmEQz6REsBNq18RaxDKLjAWt7fCjDde_iJkq8USMuuR7FrxvJiTRG_pyqqJxk6zT6H6c4ExSUU2RuKEFZ1vhec3acVis1cxs0mhe4lEqNxQxt-Dt9imuORpzmZtiWSUhwTK0_ha8qLVg9xGBo4JOtQXRnn5sBYjNe_9JPpuuWb05walQWPCu0aRdnw70_dV_yrXgQZMAc9zXcLIol-YN4qiFasNxNInacNrpd7tDvHZ7w9GP9nrl_ANKzSJ3 |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5V5QAXVN4mQPfQ9oBqxW97DwhVtFVCk6qHVMrN7MskgtppnIDyo_iPzPiRKLTi1mO0K2e1Mzv7fTu73wAcCE-aOE5C22hP28g3Apsnin4GGbKH0LiSziGHl1HvOvg6Dsc78Kd9C0PXKtuYWAVqXSg6I-96lGGLeBJ8nt3aVDSKkqttBY3aKy7M6jcytvJT_xTNe-h552ejLz27KSpgqyB2FrbOZObxQHhKaqn8iOrcahMKP0SC5milXOkgx1c6lEEWyjjUKnGMzIyREdeCdA4w4j_CfdchrheP1_zOR6hEaNuNYqJlid88B3T8pCtmZa2N6VYiDpMi_36LW9P2ZngH4d69qPlPtrbaBM_34GmDXtlJ7W7PYMfkz-Hoqpa_Xh2z0eY1V3nMjtjVRhh79QImZ_mEnIwOJFmRscXyppgzSh0wTUiUyRVDY8iqZgVT03JGF_VyRmfFTOSsyPFLK_w2Exgti1_T-bJkSszn9FSLDU9P7LjbH9he8BKuH8Qor2A3L3LzBhh24H6YcSkQbAWZEAipIuWaRPFEZLGxoLOefkQK6gfpX6UeT9Bjfc-Cj61BUtWIpFOtjp9plaz3kxQtSaU7eepGFhysO89qbZD7u3Vay6ZNgMC21p0t2F-34sqmORe5KZZlGhH4Q4xhwevaCzZ_wnFWkLpbEG_5x7oDaYZvt-TTSaUdHhBoi7gFh60nbcZ0z9jf_nfs-_C4NxoO0kH_8qIDT9pEm-O-g93FfGneI15byA_VKmHw7aGX5V-P3lg5 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB5VqYS4IN6YAN1D2wOqFb8fB4QKSdTQNopQK_Vm9uUmAuzUTkD5afw7ZvxIFFpx69Ha1Xq1Mzv7zc7sNwD73BE6DCPf1MpRJvobnhlHkj69FL0HX9uC7iHPx8HJpfflyr_agT_tWxhKq2xtYmWoVS7pjrznUIQtiCOvlzZZEZP-8OP8xqQCUhRobatp1Bpyqle_0XsrP4z6KOoDxxkOLj6fmE2BAVN6obUwVSpSJ_a4I4US0g2o5q3SPnd9dNYsJaUtLPT3pfKFl_oi9JWMLC1SrUUQK06cB2j9d0Nyijqw-2kwnnxtjwEXgRNhbzsIyUmL3OZxoOVGPT4va6ZMu6J0mObZ9Q0eVNtH4y28eztt85_YbXUkDh_DowbLsuNa-Z7Ajs6ewuGkJsNeHbGLzduu8ogdssmGJnv1DKaDbEoqR9eTLE_ZYvkzLxgFEpgiXMrEiqFoRFXBgslZOae0vYzRzTHjGcszHGmFYzOOtjP_NSuWJZO8KOjhFjvvH5thb3RmOt5zuLwXsbyATpZn-hUw7BC7fhoLjtDLSzlHgBVIW0cyjngaagO66-VH3CC_ExtW4sQR6q_rGPC-FUgiG8p0qtzxI6lC926UoCSpkGec2IEB--vO85op5O5u3VaySWMusK1VbgP21q24z2nNeabzZZkEBAURcRjwstaCzU9iXBV05A0It_Rj3YEYxLdbstm0YhL3CMIFsQEHrSZt5nTH3F__d-578AC3ZHI2Gp924WEbdbPsN9BZFEv9FsHbQrxrtgmDb_e9M_8CI89d1A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhancement+of+tumor+cell+death+by+combining+cisplatin+with+an+oncolytic+adenovirus+carrying+MDA-7%2FIL-24&rft.jtitle=Acta+pharmacologica+Sinica&rft.au=Wu%2C+Yu-mei&rft.au=Zhang%2C+Kang-jian&rft.au=Yue%2C+Xue-tian&rft.au=Wang%2C+Yi-qiang&rft.date=2009-04-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=1671-4083&rft.eissn=1745-7254&rft.volume=30&rft.issue=4&rft.spage=467&rft.epage=477&rft_id=info:doi/10.1038%2Faps.2009.16&rft.externalDocID=10_1038_aps_2009_16 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F95561A%2F95561A.jpg |